One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among ...

Immune-related AEs and infusion reactions occurred in 42% of pembrolizumab-treated patients; these were grade 3 to 5 in 10% ...

At WCLC, five-year survival data to be presented on Libtayo (PD-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancer At ESMO, longer-term results with investigational fianlimab ...

2 Similarly, the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) resulted in an ORR of 54% and a median PFS of 17.4 months. 3 “In terms of overall survival [OS], we are also seeing a ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program ...

Participants were randomly assigned in a 2:1:2 ratio to receive a single-dose baseline infusion of 750 mg of Lu AG09222, 100 mg of Lu AG09222, or placebo. The primary end point was the mean change ...

Patients who discontinued prior anti-PD-(L)1 therapy due to an anti-PD-(L)1-related toxicity (applicable to the KFA115 in combination with pembrolizumab treatment arms). - Patients with symptomatic ...

Checkpoint inhibitors—drugs such as pembrolizumab and nivolumab—work by preventing certain proteins on T cells from binding with proteins on tumor cells, which allows the T cells to better ...

Vyepti comes as a solution for intravenous infusion. Vyepti is not used to treat migraine symptoms when they occur, only to help prevent them in the first place. To learn more about how Vyepti is ...

Pembrolizumab biosimilar is under clinical development by Biocad and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an ...